Insulin-like growth factor-2 (IGF-2) activates estrogen receptor-α and-β via the IGF-1 and the insulin receptors in breast cancer cells

Growth Factors

Volumn 29, Issue 2-3, 2011, Pages 82-93

  Richardson, A E ^a   Hamilton, N ^b   Davis, W ^c   Brito, C ^a   De Leon D ^a  

^a LOMA LINDA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LOMA LINDA UNIVERSITY   (United States)

Author keywords

breast cancer; estrogen receptors; IGF 1R; IGF 2; IR

Indexed keywords

ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; INSULIN RECEPTOR; SOMATOMEDIN B; SOMATOMEDIN C;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CELL FRACTIONATION; CELL ORGANELLE; GENE TRANSLOCATION; HORMONE RECEPTOR INTERACTION; HUMAN; HUMAN CELL; MITOCHONDRION; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

AGED; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MEMBRANE; CELL NUCLEUS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MIDDLE AGED; MITOCHONDRIA; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 79955790378     PISSN: 08977194     EISSN: 10292292     Source Type: Journal    
DOI: 10.3109/08977194.2011.565003     Document Type: Article

References (62)

1. Abbas A, Yakar S, LeRoith D, Brodt P. 2007. The role of the IGF system in cancer growth and metastasis: Overview and recent insights. Endocrinology 28(1):20-47. (Pubitemid 46220849)
2. Anders C, Carey LA. 2008. Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22(11): 1233-1239, discussion 1239-1240, 1243.
3. Arpino G, Wiechmann L, Osborne CK, SchiffR. 2008. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: Molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 29(2):217-233. (Pubitemid 351519691)
4. Bates P, Fisher R, Ward A, Richardson L, Hill DJ, Graham CF. 1995. Mammary cancer in transgenic mice expressing insulin-like growth factor II (IGF-II). Br J Cancer 72(5):1189-1193.
5. Bjornstrom L, Sjoberg M. 2005. Mechanisms of estrogen receptor signaling: Convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19(4):833-842. (Pubitemid 40397050)
6. Brisken C, Ayyannan A, Nguyen C, Heineman A, Reinhardt F, Tan J, Dey SK, Dotto GP, Weinberg RA. 2002. IGF-2 is a mediator ofprolactin-induced morphogenesis in the breast. Dev Cell 3(6):877-887. (Pubitemid 35460787)
7. Byrd JC, Devi GR, de Souza AT, Jirtle RL, MacDonald RG. 1999. Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphate receptor by cancer-associated missense mutations. J Biol Chem 274:24408-24416.
8. Chao W, D'Amore P. 2008. IGF2: Epigenetic regulation and role in development and disease. Cytokine Growth Factor Rev 19: 111-120. (Pubitemid 351382280)
9. Chen JQ, Delannoy M, Cooke C, Yager JD. 2004. Mitochondrial localization of ERalpha and ERbeta in human MCF7 cells. Am J Physiol Endocrinol Metab 286(6):E1011-E1022. (Pubitemid 38668826)
10. Chen Y, Boyartchuk V, Lewis BC. 2009. Differential roles of insulin-like growth factor receptor-and insulin receptor-mediated signaling in the pheonotypes of hepatocellular carcinoma cells. Neoplasia 11(9):835-845.
11. Demonacos CV, Karayanni N, Hatzoglou E, Tsiriyiotis C, Spandidos DA, Sekeris CE. 1996. Mitochondrial genes as sites ofprimary action of steroid hormones. Steroids 61(4):226-232. (Pubitemid 26144427)
12. De León DD, Bakker B, Wilson DM, Hintz RL, Rosenfeld R. 1988. Demonstration of insulin-like growth factor (IGF-I and-II) receptors and binding protein in human breast cancer cells lines. Biochem Biophys Res Commun 152:398-405.
13. De León DD, Wilson DM, Bakker B, Lamsom G, Hintz RL, Rosenfeld R. 1989. Characterization of insulin-like growth factor (IGF) binding proteins from human breast cancer cells. Mol Endocrinol 3:567-574. (Pubitemid 19085056)
14. De León DD, Powers M, Wilson DM, Rosenfeld RG. 1992. Effects of insulin-like growth factors (IGFs) and IGF receptor antibodies in human breast cancer cell proliferation. Growth Factors 6:327-336.
15. Erbay E, Park IH, Nuzzi PD, Schoenherr CJ, Chen J. 2003. IGF-II transcription in skeletal myogenesis is controlled by mTOR and nutrients. J Cell Biol 163(5):931-936. (Pubitemid 37541870)
16. Fagan D, Yee D. 2008. Crosstalk between IGF1R and estrogen receptor signaling in breast cancer. J Mammary Gland Biol Neoplasia 13:423-429.
17. Flynn JM, Dimitrijevich SD, Younes M, Skliris G, Murphy LC, Cammarata PR. 2008. Role ofwild-type estrogen receptor-beta in mitochondrial cytoprotection of cultured normal male and female human lens epithelial cells. Am J Physiol Endocrinol Metab 295(3):E637-E647.
18. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, Kodagoda D, Stasny V, Cunningham HT, Wistuba II, Tomlinson G, Tonk V, Ashfaq R, Leitch AM, Minna JD, Shay JW. 1998. Characterization ofpaired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer 78:766-774. (Pubitemid 28530401)
19. Ge Y, Sun Y, Chen J. 2011. IGF-II is regulated by microRNA-125b in skeletal myogenesis. J Cell Biol 192(1):69-81.
20. Gee JM, Robertson JF, Gutteridge E, Ellis IO, Pinder SE, Rubini M, Nicholson RI. 2005. Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestro-gen receptor activity in clinical breast cancer. Endocr Relat Cancer 12(Supplement 1):S99-S111. (Pubitemid 41395417)
21. Goel HL, Moro L, King M, Teider N, Centrella M, McCarthy TL, Holgado-Madruga M, Wong AJ, Marra E, Languino LR. 2006. ß1 integrins modulate cell adhesion by regulating insulin-like growth factor-II levels in the microenvironment. Cancer Res 66: 331-342. (Pubitemid 43166040)
22. Goldfine ID, Papa V, Vigneri R, Siiteri P, Rosenthal S. 1992. Progestin regulation of insulin and insulin-like growth factor I receptors in cultured human breast cancer cells. Breast Cancer Res Treat 22(1):69-79.
23. Hackett AJ, Smith HS, Springer EL, Owens RB, Nelson-Rees WA, Riggs JL, Gardner MB. 1977. Two syngeneic cell lines from human breast tissue: The aneuploid mammary epithelial (Hs 578T) and the diploid myoepithelial (Hs 578Bst) cell lines. J Natl Cancer Inst 58:1795-1806. (Pubitemid 8118760)
24. Hamelers IHL, Steenbergh PH. 2003. Interactions between estrogen and insulin-like growth factor signaling pathways in human breast tumor cells. Endocr Relat Cancer 10:331-345. (Pubitemid 36758659)
25. Ishida S, Noda M, Kuzuya N, Kubo F, Yamada S, Yamanaka T, Isozaki O, Hizuka N, Kanazawa Y 1995. Big insulin-like growth factor II-producing hepatocellular carcinoma associated with hypoglycemia. Intern Med 34(12):1201-1206.
26. Kahlert S, Nuedling S, van Eickels M, Vetter H, Meyer R, Grohe C. 2000. Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway. J Biol Chem 275(24):18447-18453. (Pubitemid 30414803)
27. Kato S, Endoh H, Masuhiro Y, Kitamoto T, Uchiyama S, Sasaki H, Masushige S, Gotoh Y, Nishida E, Kawashima H, Metzger D, Chambon P. 1995. Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase. Science 270(5241):1491-1494.
28. Kitadai Y, Yamazaki H, Yasui W, Kyo E, Yokozaki H, Kajiyama G, Johnson AC, Pastan I, Tahara E. 1993. GC factor represses transcription of several growth factor/receptor genes and causes growth inhibition of human gastric carcinoma cell lines. Cell Growth Differ 4(4):291-296.
29. Klotz DM, Hewitt SC, Ciana P, Raviscioni M, LindzeyJK, FoleyJ, Maggi A, DiAugustine RP, Korach KS. 2002. Requirement of estrogen receptor-alpha in insulin-like growth factor-1 (IGF-1)-induced uterine responses and in vivo evidence for IGF-1/estrogen receptor cross-talk. J Biol Chem 277(10):8531-8537. (Pubitemid 34968316)
30. Kuiper GG, Carlsson B, Grandien K, Enmark E, Haggblad J, Nilsson S, Gustafsson JA. 1997. Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta. Endocrinology 138(3):863-870. (Pubitemid 27089735)
31. Lannigan DA. 2003. Estrogen receptor phosphorylation. Steroids 68(1):1.
32. LeRoith D, Baserga R, Helman L, Roberts CT,Jr. 1995. Insulin-like growth factors and cancer. Ann Intern Med 122(1):54-59.
33. Morali OG, Delmas V, Moore R, Jeanney C, Thiery JP, Larue L. 2001. IGF-II induces rapid beta-catenin relocation to the nucleus during epithelium to mesenchyme transition. Oncogene 20:4942-4950. (Pubitemid 32769784)
34. Nilsen J, Diaz Brinton R. 2003. Mechanism ofestrogen-mediated neuroprotection: Regulation ofmitochondrial calcium and Bcl-2 expression. Proc Natl Acad Sci USA 100(5):2842-2847. (Pubitemid 36297586)
35. Perks CM, Vernon EG, Rosendahl AH, Tonge D, HollyJM. 2007. IGF-II and IGFBP-2 differentially regulate PTEN in human breast cancer cells. Oncogene 26(40):5966-5972.
36. Pezzino V, Papa V, Milazzo B. 1996. Insulin-like growth factor-I receptors in breast cancer. Ann NYAcad Sci 784(1):189-201. (Pubitemid 26194763)
37. Pietras RJ, Marquez-Garban DC 2007. Membrane-associated estrogen receptor signaling pathways in human cancers. Clin CancerRes 13(16):4672-4676. (Pubitemid 47294772)
38. Poola I, Fuqua SA, De Witty RL, Abraham J, Marshallack JJ, Liu A. 2005. Estrogen receptor alpha-negative breast cancer tissues express significant levels of estrogen-independent transcription factors, ERbeta1 and ERbeta5: Potential molecular targets for chemoprevention. Clin CancerRes 11(20):7579-7585. (Pubitemid 41507721)
39. Pravtcheva DD, Wise TL. 1998. Metasizing mammary carcinomas in H19 enhancers-Igf2 transgenic mice. J Exp Zool 281:43-57. (Pubitemid 28202963)
40. Pravtcheva DD, Wise TL. 2003. Transgene instability in mice injected with an in vitro methylated Igf2 gene. Mutation Res 529: 35-50. (Pubitemid 37013387)
41. Rasmussen AA, Cullen KJ. 1998. Paracrine/autocrine regulation of breast cancer by the insulin-like growth factors. Breast Cancer Res Treat 47(3):219-233. (Pubitemid 28059819)
42. Richards RG, DiAugustine RP, Petrusz P, Clark GC, Sebastian J. 1996. Estradiol stimulates tyrosine phosphorylation of the insulin-like growth factor-1 receptor and insulin receptor substrate-1 in the uterus. Proc Natl Acad Sci USA 93(21): 12002-12007. (Pubitemid 26347238)
43. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. 2004. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin CancerRes 10(1 Pt 2):331S-336S. (Pubitemid 38116639)
44. Sciacca L, Costantino A, Pandini G, Mineo R, Frasca F, Scalia P, Sbraccia P, Goldfine ID, Vigneri R, Belfiore A. 1999. Insulin receptor activation by IGF-II in breast cancers: Evidence for a new autocrine/paracrine mechanism. Oncogene 18(15): 2471-2479. (Pubitemid 29206160)
45. Sekeris CE. 1990. The mitochondrial genome: A possible primary site of action of steroid hormones. In Vivo 4(5):317-320.
46. Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. 2004. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ERHER2-positive breast cancer. J Natl Cancer Inst 96(12):926-935. (Pubitemid 38868139)
47. Singer C, Mogg M, Koestler W, Pacher M, Marton E, Kubista E, Kubista E, Schreiber M. 2004. Insulin like Growth Factor (IGF)-I and IGF-II Serum Concentrations in Patients with Benign and Malignant Breast Lesions. Clin Cancer Res 10: 4003-4009. (Pubitemid 38812474)
48. Singh SK, Moretta D, Almaguel F, Wall NR, De Leon M, De Leon D. 2007. Differential effect of proIGF-II and IGF-II on resveratrol induced cell death by regulating survivin cellular localization and mitochondrial depolarization in breast cancer cells. Growth Factors 25(6):363-372. (Pubitemid 351455002)
49. Singh SK, Moretta D, Almaguel F, De Leon M, De Leon D. 2008. Precursor IGF-II mature IGF-II induce Bcl-2 and Bcl-XL expression through different signaling pathways in breast cancer cells. Growth Factors 26:92-103. (Pubitemid 351584061)
50. Song RX, Fan P, Yue W, Chen Y, Santen RJ. 2006. Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancer. Endocr Relat Cancer 13(Supplement 1): S3-13.
51. Sukmi K-P, Lee YI, Lee YI. 2003. PTEN modulates insulin-like growth factor II (IGF-II)-mediated signaling; the protein phosphatasectivity of PTEN downregulates IGF-II expression in hepatoma cells. FEBS Letters 545(2-3):203-208. (Pubitemid 36694702)
52. Szepeshazi K, Schally AV, Halmos G, Groot K, Radulovic S. 1992. Growth inhibition of estrogen-dependent and estrogen-independent MXT mammary cancers in mice by the bombesin and gastrin-releasing peptide antagonist RC-3095. JNatl Cancer Inst 84(24):1915-1922. (Pubitemid 23004620)
53. Toretsky JA, Helman LJ. 1996. Involvement of IGF-II in human cancer. J Endocrinol 149:367-372. (Pubitemid 26196067)
54. Valentinis B, Baserga R. 2001. IGF-1 receptor signalling in transformation and differentiation. Mol Path 54(3):133-137. (Pubitemid 32539602)
55. Vyas S, Asmerom Y, De Leon DD. 2005. Resveratrol regulates insulin-like growth factor-II in breast cancer cells. Endocrin-ology 146(10):4224-4233. (Pubitemid 41324018)
56. Wang J, Green PS, Simpkins JW. 2001. Estradiol protects against ATP depletion, mitochondrial membrane potential decline and the generation of reactive oxygen species induced by 3-nitroproprionic acid in SK-N-SH human neuroblastoma cells. JNeurochem 77(3):804-811. (Pubitemid 32466777)
57. Webb P, Nguyen P, Valentine C, Lopez GN, Kwok GR, McInerney E, Katzenellenbogen BS, Enmark E, Gustafsson J, Nilsson S, KushnerPJ. 1999.TheestrogenreceptorenhancesAP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions. Mol Endocrinol 13(10): 1672-1685. (Pubitemid 30645272)
58. Xu Y, Traystman RJ, Hurn PD, Wang MM. 2004. Membrane restraint of estrogen receptor alpha enhances estrogen-depen-dent nuclear localization and genomic function. Mol Endocrinol 18(1):86-96. (Pubitemid 38073156)
59. Yang SH, Liu R, Perez EJ, Wen Y, Stevens SM Jr, Valencia T, Brun-Zinkernagel AM, Prokai L, Will Y, Dykens J, Koulen P, Simpkins JW. 2004. Mitochondrial localization of estrogen receptor beta. Proc Natl Acad Sci USA 101(12):4130-4135. (Pubitemid 38410620)
60. Yballe CM, Vu TH, Hoffman AR. 1996. Imprinting and expression of insulin-like growth factor-II and H19 in normal breast tissue and breast tumor. J Clin Endocrinol Metab 81(4): 1607-1612. (Pubitemid 26118600)
61. Zhang L, Kashanchi F, Zhan Q, Brady JN, Fornace AJ, Seth P, Helman LJ. 1996. Regulation ofinsulin-like growth factor II P3 promoter by p53: A potential mechanism for tumorigenesis. CancerRes 56:1367-1373. (Pubitemid 26080981)
62. Zhang LJ, Zhan QM, Zhan SL, Kashanchi F, Fornace AJ, Seth P, Helman LJ. 1998. p53 regulates human insulin-like growth factor II gene expression through active P4 promoter in rhabdomyosarcoma cells. DNA Cell Biol 17:1.